SCHEMBL24427296

SCHEMBL24427296

CC(=O)ONC(=N)c1ccc(NC(=O)OC(C)(C)C)nc1F

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.34
ATR Q13535 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP17A1 P05093 3/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
PRMT1 Q99873 1/20 0.32
LCK P06239 1/20 0.31
SYK P43405 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL29863168 0.87 PRMT1 (0.36) SCN9AATRNPSR1CYP17A1GSK3B
SCHEMBL24726508 0.86 ATR (0.38) SCN9AATRCYP17A1GSK3BDYRK1A
SCHEMBL24427294 0.85 PRMT1 (0.38) SCN9AATRCYP17A1GSK3BDYRK1A
Hydrochloric Acid SCHEMBL29863034 0.84 PRMT1 (0.38) SCN9AATRCYP17A1GSK3BDYRK1A
SCHEMBL15060517 0.83 ATR (0.39) SCN9AATRCYP17A1GSK3BDYRK1A
SCHEMBL19205217 0.83 ATR (0.39) SCN9AATRCYP17A1GSK3BDYRK1A
SCHEMBL38663529 0.80 ATR (0.49) SCN9AATRCYP17A1GSK3BDYRK1A
SCHEMBL38661717 0.80 ATR (0.49) SCN9AATRCYP17A1GSK3BDYRK1A
SCHEMBL24427232 0.77 AKT1 (0.36) SCN9AATRCYP17A1GSK3BDYRK1A
SCHEMBL29862857 0.77 AKT1 (0.36) SCN9AATRCYP17A1GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 US disclosed
EP-3998263-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 SCN9A 1993/4885ATR 3661/4885NPSR1 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.